Brainomix and Boehringer Expand AI Partnership for Earlier Pulmonary Fibrosis Detection
Brainomix has expanded its partnership with Boehringer Ingelheim to advance clinical use of e-Lung, an AI imaging platform designed to detect progressive pulmonary fibrosis earlier in its course. The FDA-cleared platform automatically detects and quantifies abnormalities on thoracic CT scans, including subtle changes across multiple timepoints.
The expanded collaboration centers on PROGRESS-PPF, a prospective multicenter study in the U.S. that will evaluate whether routine use of e-Lung supports earlier clinical diagnosis of progressive pulmonary fibrosis.
Earlier Detection Shown in Retrospective Study
The expansion follows results from REVISE-PPF, a retrospective study conducted with the University of Chicago, Weill Cornell Medical Center, and the University of Alabama at Birmingham. The study found that e-Lung identified patients with radiologic evidence of progressive pulmonary fibrosis up to 28 months earlier than local clinical diagnoses.
e-Lung has been clinically validated to measure lung features associated with interstitial lung diseases, which are precursors to progressive pulmonary fibrosis.
What This Means for Operations
For managers overseeing clinical operations or AI implementation, this partnership demonstrates how validated imaging tools can integrate into existing diagnostic workflows. Earlier detection directly affects patient management timelines and treatment planning.
Results from the retrospective study will be presented at the American Thoracic Society International Conference in Orlando on May 17.
For those managing clinical AI initiatives, understanding how partnerships between technology vendors and pharmaceutical companies advance validation can inform procurement and deployment decisions. AI for Healthcare applications continue to shift from research settings into routine clinical practice.
Your membership also unlocks:
